Finix 20 mg (Tablet (Enteric Coated))

Title

• Finix Gastro-resistant tablets

Categories

• Medicine
• Gastrointestinal Health
• Pharmacology
• Gastric Acid Reducer

Description

• Used for the treatment of active duodenal ulcer, active benign gastric ulcer, symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD), long-term management of GERD, Zollinger-Ellison Syndrome, and for eradication of Helicobacter pylori in patients with peptic ulcer disease
• Suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell
• Various recommended oral doses for different conditions and patient populations
• Should be taken in the morning before eating
• Cautioned that tablets should not be chewed or crushed, but should be swallowed whole
• Can produce side effects such as headache, diarrhea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, and dizziness

Color Options

• Not applicable

Dimensions

• Not applicable

Functions

• Suppression of gastric acid secretion
• Treatment for gastrointestinal health conditions

Materials

• Not applicable

Technical Specifications

• Molecular Formula: C18H21N3O3S
• Chemical Structure: Image provided

Design Elements

• Enteric coating for gastro-resistance

Usability Features

• Can be taken once daily for convenience
• Suitable for long-term management
• Recommended doses for pediatric patients

Dosage

• Varies based on the condition being treated
• 20 mg to be taken once daily in the morning for active duodenal ulcer and active benign gastric ulcer
• 20 mg to be taken once daily for four to eight weeks for erosive or ulcerative gastro-esophageal reflux disease
• For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response
• 10 mg once daily for symptomatic treatment of moderate to very severe gastro-esophageal reflux disease
• 5 mg to 10 mg once daily for 12 weeks for pediatric patients
• Starting dose of 60 mg once daily for Zollinger-Ellison Syndrome with possible titration upwards
• Combination therapy for the eradication of Helicobacter pylori

Interaction

• Potential interaction with compounds whose absorption is pH dependent
• Co-administration with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels
• No interaction with liquid antacids observed
• PPIs, including rabeprazole, should not be co-administered with atazanavir

Contraindications

• Hypersensitivity to the active substance or to any of the excipients
• Contra-indicated in pregnancy and during breastfeeding

Side Effects

• Headache
• Diarrhea
• Abdominal pain
• Vomiting
• Constipation
• Dry mouth
• Increased or decreased appetite
• Muscle pain
• Drowsiness
• Dizziness

Pregnancy & Lactation

• US FDA pregnancy category 'C'
• No adequate and well-controlled studies in pregnant women
• Likely to be excreted in human milk

Precautions & Warnings

• Symptomatic response to therapy does not preclude the presence of gastric or esophageal malignancy
• Patients on long-term treatment should be kept under regular surveillance
• Modestly increased risk of hip, wrist, and spine fracture, especially in the elderly or presence of other recognized risk factors
• A risk of cross-hypersensitivity reactions with other proton pump inhibitors or substituted benzimidazoles cannot be excluded
• Blood dyscrasias, hepatic enzyme abnormalities, hypomagnesaemia, and interference with laboratory tests reported
• Caution advised for patients with severe hepatic dysfunction
• Possible increase in the risk of gastrointestinal infections
• Severe hypomagnesaemia reported in patients treated with PPIs for at least three months
• Reduction in the absorption of vitamin B12 and association with subacute cutaneous lupus erythematosus

Use in Special Populations

• No dosage adjustment necessary for patients with renal or hepatic impairment
• Not recommended for use in children

Overdose Effects

• Maximum established exposure has not exceeded 60 mg twice daily, or 160 mg once daily
• Effects are generally minimal, reversible without further medical intervention
• No specific antidote known

Therapeutic Class

• Proton Pump Inhibitor

Storage Conditions

• Keep below 30°C temperature, away from light & moisture
• Keep out of the reach of children

Related Brands

• Acifix 20 mg (Capsule (Enteric Coated)) - beximco-pharmaceuticals-ltd